TG Therapeutics (TGTX) Misses Q2 EPS by 4c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.33), $0.04 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.1 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
• The First Of Long Island (FLIC) Misses Q1 EPS by 3c